Hamburg - 12 June 2013: Shareholders of Evotec AG today approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting.- read more
*TARGET PGB (PEPTIDOGLYCAN BIOSYNTHESIS) IS THE FOCUS OF COLLABORATION
DESIGNED TO DEVELOP NOVEL FAMILY OF ANTIBACTERIAL DRUGS BASED ON HIGHLY
Hamburg, Germany and Cambridge, MA - 16 May 2013: Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.
- STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION EFFICIENCY - EVOTEC'S DRUG DISCOVERY PLATFORM GENERATES GROWTH
- NEW HORMONE IDENTIFIED AS PART OF THE CUREBETA INITIATIVE
- GUIDANCE 2013 CONFIRMED
Hamburg, Germany - 14 May 2013: Evotec AG today reported financial results and corporate updates for the first quarter of 2013.- read more